Pathology & Oncology Research

, Volume 25, Issue 1, pp 279–288 | Cite as

Possible Predictive Markers of Response to Therapy in Esophageal Squamous Cell Cancer

  • Laszló Zoltan
  • Robert Farkas
  • Andrew V. Schally
  • Eva Pozsgai
  • Andras Papp
  • Laura Bognár
  • Tamas Tornoczki
  • Laszlo Mangel
  • Szabolcs BellyeiEmail author
Original Article


The aim of the present study was to investigate the relationship between the intensity of biomarker expression and the response to radiochemotherapy in patients with advanced esophageal squamous cell cancer (ESCC). Ninety-two patients with locally advanced ESCC were examined retrospectively. Pre-treatment tumor samples were stained for proteins SOUL, Hsp 16.2, Growth Hormone-Releasing Hormone Receptor (GHRH-R) and p-Akt using immunhistochemistry methods. Kaplan-Meier curves were used to show the relationship between intensity of expression of biomarkers and clinical parameters and 3-year OS. A significant correlation was found between high intensity staining for Hsp 16.2, p-Akt and SOUL and poor response to NRCT. Application of a higher dose of radiation and higher dose of cisplatin resulted in better clinical and histopathological responses, respectively. Among the clinical parameters, the localization of the tumor in the upper-third of the esophagus and less than 10% weight loss were independent prognostic factors for increased 3-year OS. Hsp16.2, p-Akt and SOUL are predictors of negative response to NRCT, therefore these biomarkers may become promising targets for therapy. Furthermore, level of expression of p-Akt, weight loss and the localization of the tumor are significant factors in the prediction of OS in ESCC.


Radiochemotherapy AKT Small heat shock protein Predictiv factors Esopageal cancer 


Compliance with Ethical Standards

Conflict of interest

All authors declare that he/she has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies animals performed by any of the authors.

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study. This was approved by the Local Ethics Committee.


  1. 1.
    Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386. Google Scholar
  2. 2.
    Keighley MR (2003) Gastrointestinal cancers in Europe. Aliment Pharmacol Ther 18(Suppl 3):7–30Google Scholar
  3. 3.
    Mariette C, Piessen G, Triboulet JP (2007) Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. The Lancet Oncology 8(6):545–553. Google Scholar
  4. 4.
    Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J, Australasian Gastro-Intestinal Trials G (2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. The Lancet Oncology 8(3):226–234. Google Scholar
  5. 5.
    Hanna A, Birla R, Iosif C, Boeriu M, Constantinoiu S (2016) Benefits and Disadvantages of Neoadjuvant Radiochemotherapy (RCT) in the Multimodal Therapy of Squamous Esophageal Cancer (ESC). Chirurg 111(1):12–25Google Scholar
  6. 6.
    Nakajima M, Kato H (2013) Treatment options for esophageal squamous cell carcinoma. Expert Opin Pharmacother 14(10):1345–1354. Google Scholar
  7. 7.
    Ordu AD, Nieder C, Geinitz H, Scherer V, Kup PG, Schuster T, Combs SE, Fakhrian K (2014) Association between radiation dose and pathological complete response after preoperative radiochemotherapy in esophageal squamous cell cancer. Anticancer Res 34(12):7255–7261Google Scholar
  8. 8.
    Geh JI, Bond SJ, Bentzen SM, Glynne-Jones R (2006) Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 78(3):236–244. Google Scholar
  9. 9.
    Gillham CM, Reynolds J, Hollywood D (2007) Predicting the response of localised oesophageal cancer to neo-adjuvant chemoradiation. World Journal of Surgical Oncology 5:97. Google Scholar
  10. 10.
    Sarbia M, Ott N, Puhringer-Oppermann F, Brucher BL (2007) The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodally treated squamous cell carcinoma of the oesophagus. Br J Cancer 97(10):1404–1408. Google Scholar
  11. 11.
    Zhu Z, Yu W, Fu X, Sun M, Wei Q, Li D, Chen H, Xiang J, Li H, Zhang Y, Zhao W, Zhao K (2015) Phosphorylated AKT1 is associated with poor prognosis in esophageal squamous cell carcinoma. Journal of experimental & clinical cancer research : CR 34:95. Google Scholar
  12. 12.
    Ui T, Morishima K, Saito S, Sakuma Y, Fujii H, Hosoya Y, Ishikawa S, Aburatani H, Fukayama M, Niki T, Yasuda Y (2014) The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal squamous cell carcinoma cell lines via the Akt/XIAP pathway. Oncol Rep 31(2):619–624. Google Scholar
  13. 13.
    Jin Z, Yan W, Jin H, Ge C, Xu Y (2016) Psoralidin inhibits proliferation and enhances apoptosis of human esophageal carcinoma cells via NF-kappaB and PI3K/Akt signaling pathways. Oncol Lett 12(2):971–976. Google Scholar
  14. 14.
    Wang X, Li X, Li C, He C, Ren B, Deng Q, Gao W, Wang B (2016) Aurora-A modulates MMP-2 expression via AKT/NF-kappaB pathway in esophageal squamous cell carcinoma cells. Acta Biochim Biophys Sin 48(6):520–527. Google Scholar
  15. 15.
    Xue L, Yang L, Jin ZA, Gao F, Kang JQ, Xu GH, Liu B, Li H, Wang XJ, Liu LJ, Wang BL, Liang SH, Ding J (2014) Increased expression of HSP27 inhibits invasion and metastasis in human esophageal squamous cell carcinoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 35(7):6999–7007. Google Scholar
  16. 16.
    Chen JH, Chen LM, Xu LY, Wu MY, Shen ZY (2006) Expression and significance of heat shock proteins in esophageal squamous cell carcinoma. Zhonghua zhong liu za zhi [Chinese journal of oncology] 28(10):758–761Google Scholar
  17. 17.
    Farkas R, Pozsgai E, Bellyei S, Cseke L, Szigeti A, Vereczkei A, Marton S, Mangel L, Horvath OP, Papp A (2011) Correlation between tumor-associated proteins and response to neoadjuvant treatment in patients with advanced squamous-cell esophageal cancer. Anticancer Res 31(5):1769–1775Google Scholar
  18. 18.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (3):205–216Google Scholar
  19. 19.
    Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G et al (1994) Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 73(11):2680–2686Google Scholar
  20. 20.
    Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, Seitz JF, Buecher B, Mackiewicz R, Ducreux M, Bedenne L (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 24(28):4620–4625. Google Scholar
  21. 21.
    Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351(17):1731–1740. Google Scholar
  22. 22.
    Bellyei S, Szigeti A, Boronkai A, Pozsgai E, Gomori E, Melegh B, Janaky T, Bognar Z, Hocsak E, Sumegi B, Gallyas F, Jr. (2007) Inhibition of cell death by a novel 16.2 kD heat shock protein predominantly via Hsp90 mediated lipid rafts stabilization and Akt activation pathway. Apoptosis 12 (1):97–112. doi:
  23. 23.
    Bellyei S, Szigeti A, Pozsgai E, Boronkai A, Gomori E, Hocsak E, Farkas R, Sumegi B, Gallyas F, Jr. (2007) Preventing apoptotic cell death by a novel small heat shock protein. Eur J Cell Biol 86 (3):161–171. doi:
  24. 24.
    Szigeti A, Bellyei S, Gasz B, Boronkai A, Hocsak E, Minik O, Bognar Z, Varbiro G, Sumegi B, Gallyas F, Jr. (2006) Induction of necrotic cell death and mitochondrial permeabilization by heme binding protein 2/SOUL. FEBS Lett 580 (27):6447–6454. doi:
  25. 25.
    Somji S, Sens MA, Lamm DL, Garrett SH, Sens DA (2001) Metallothionein isoform 1 and 2 gene expression in the human bladder: evidence for upregulation of MT-1X mRNA in bladder cancer. Cancer Detect Prev 25(1):62–75Google Scholar
  26. 26.
    de Manzoni G, Pedrazzani C, Laterza E, Pasini F, Grandinetti A, Bernini M, Ruzzenente A, Zerman G, Tomezzoli A, Cordiano C (2005) Induction chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus: impact of increased dosage on long-term results. Ann Thorac Surg 80(4):1176–1183. Google Scholar
  27. 27.
    Pasini F, de Manzoni G, Pedrazzani C, Grandinetti A, Durante E, Gabbani M, Tomezzoli A, Griso C, Guglielmi A, Pelosi G, Maluta S, Cetto GL, Cordiano C (2005) High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel and concurrent radiotherapy. Annals of oncology : official journal of the European Society for Medical Oncology 16(7):1133–1139. Google Scholar
  28. 28.
    Hanna A, Birla R, Iosif C, Boeriu M, Tomsa R, Puscasu A, Constantinoiu S (2015) Evaluation of Neoadjuvant Radiochemotherapy Response (RCT) in Squamous Esophageal Cancer (ESC) and Implications in Therapeutic Conduct. Chirurg 110(3):214–223Google Scholar
  29. 29.
    Parcellier A, Schmitt E, Brunet M, Hammann A, Solary E, Garrido C (2005) Small heat shock proteins HSP27 and alphaB-crystallin: cytoprotective and oncogenic functions. Antioxid Redox Signal 7(3–4):404–413. Google Scholar
  30. 30.
    Xu Y, Chen Z, Zhang G, Xi Y, Sun R, Wang X, Wang W, Chai F, Li X (2016) HSP90B1 overexpression predicts poor prognosis in NSCLC patients. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 37(10):14321–14328. Google Scholar
  31. 31.
    Chang X, Zhao J, Tian F, Jiang Y, Lu J, Ma J, Zhang X, Jin G, Huang Y, Dong Z, Liu K, Dong Z (2016) Aloe-emodin suppresses esophageal cancer cell TE1 proliferation by inhibiting AKT and ERK phosphorylation. Oncol Lett 12(3):2232–2238. Google Scholar
  32. 32.
    Sha K, Yeh S, Chang C, Nastiuk KL, Krolewski JJ (2015) TNF signaling mediates an enzalutamide-induced metastatic phenotype of prostate cancer and microenvironment cell co-cultures. Oncotarget 6(28):25726–25740.  10.18632/oncotarget.4535 Google Scholar
  33. 33.
    Li X, Wang S, Ren H, Ma J, Sun X, Li N, Liu C, Huang K, Xu M, Ming L (2016) Molecular correlates and prognostic value of tmTNF-alpha expression in colorectal cancer of 5-Fluorouracil-Based Adjuvant Therapy. Cancer biology & therapy 17(6):684–692. Google Scholar
  34. 34.
    Plonowski A, Schally AV, Letsch M, Krupa M, Hebert F, Busto R, Groot K, Varga JL (2002) Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor. Prostate 52(3):173–182. Google Scholar
  35. 35.
    Kahan Z, Arencibia JM, Csernus VJ, Groot K, Kineman RD, Robinson WR, Schally AV (1999) Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers. J Clin Endocrinol Metab 84(2):582–589. Google Scholar
  36. 36.
    Garcia-Fernandez MO, Schally AV, Varga JL, Groot K, Busto R (2003) The expression of growth hormone-releasing hormone (GHRH) and its receptor splice variants in human breast cancer lines; the evaluation of signaling mechanisms in the stimulation of cell proliferation. Breast Cancer Res Treat 77(1):15–26Google Scholar
  37. 37.
    Rekasi Z, Czompoly T, Schally AV, Halmos G (2000) Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers. Proc Natl Acad Sci U S A 97(19):10561–10566. Google Scholar
  38. 38.
    Halmos G, Schally AV, Varga JL, Plonowski A, Rekasi Z, Czompoly T (2000) Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone. Proc Natl Acad Sci U S A 97(19):10555–10560. Google Scholar
  39. 39.
    Szereday Z, Schally AV, Szepeshazi K, Bajo AM, Hebert F, Halmos G, Nagy A (2003) Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238. Int J Oncol 22(5):1141–1146Google Scholar
  40. 40.
    Hohla F, Moder A, Mayrhauser U, Hauser-Kronberger C, Schally AV, Varga JL, Zarandi M, Buchholz S, Huber R, Aigner E, Ritter M, Datz C (2008) Differential expression of GHRH receptor and its splice variant 1 in human normal and malignant mucosa of the oesophagus and colon. Int J Oncol 33(1):137–143Google Scholar
  41. 41.
    Wu CC, Chang CM, Hsu TW, Lee CH, Chen JH, Huang CY, Lee CC (2016) The effect of individual and neighborhood socioeconomic status on esophageal cancer survival in working-age patients in Taiwan. Medicine 95(27):e4140. Google Scholar
  42. 42.
    Koppert LB, Lemmens VE, Coebergh JW, Steyerberg EW, Wijnhoven BP, Tilanus HW, Janssen-Heijnen ML (2012) Impact of age and co-morbidity on surgical resection rate and survival in patients with oesophageal and gastric cancer. Br J Surg 99(12):1693–1700. Google Scholar
  43. 43.
    Kandaz M, Ertekin MV, Bilici M (2012) Retrospective analysis of patients with esophageal cancer treated with radiotherapy and/or chemoradiotherapy. Tumori 98(4):445–450. Google Scholar
  44. 44.
    Neuhof D, Neumayer F, Einbeck W, Haschemian K, Mai SK, Hochhaus A, Willeke F, Rudi J, Debus J, Wenz F (2005) Retrospective evaluation of combined modality treatment and prognostic factors in patients with esophageal cancer. Acta Oncol 44(2):168–173. Google Scholar
  45. 45.
    Di Fiore F, Lecleire S, Pop D, Rigal O, Hamidou H, Paillot B, Ducrotte P, Lerebours E, Michel P (2007) Baseline nutritional status is predictive of response to treatment and survival in patients treated by definitive chemoradiotherapy for a locally advanced esophageal cancer. Am J Gastroenterol 102(11):2557–2563. Google Scholar
  46. 46.
    Zemanova M, Novak F, Vitek P, Pazdro A, Smejkal M, Pazdrova G, Petruzelka L (2012) Outcomes of patients with oesophageal cancer treated with preoperative chemoradiotherapy, followed by tumor resection: influence of nutritional factors. Journal of BUON : official journal of the Balkan Union of Oncology 17(2):310–316Google Scholar
  47. 47.
    Papp A, Cseke L, Farkas R, Pavlovics G, Horvath G, Varga G, Szigeti A, Bellyei S, Marton S, Poto L, Kalmar K, Vereczkei A, Pozsgai E, Horvath OP (2010) Chemo-radiotherapy in locally advanced squamous cell oesophageal cancer--are upper third tumours more responsive? Pathol Oncol Res 16(2):193–200. Google Scholar
  48. 48.
    Papp A, Cseke L, Pavlovics G, Farkas R, Varga G, Marton S, Poto L, Esik O, Horvath OP (2007) The effect of preoperative chemo-radiotherapy in the treatment of locally advanced squamous cell carcinoma in the upper- and middle-thirds of the esophagus. Magy Seb 60(3):123–129. Google Scholar

Copyright information

© Arányi Lajos Foundation 2017

Authors and Affiliations

  • Laszló Zoltan
    • 1
    • 2
  • Robert Farkas
    • 1
    • 2
  • Andrew V. Schally
    • 2
    • 3
  • Eva Pozsgai
    • 2
    • 3
  • Andras Papp
    • 2
    • 4
  • Laura Bognár
    • 2
    • 4
  • Tamas Tornoczki
    • 2
    • 5
  • Laszlo Mangel
    • 1
    • 2
  • Szabolcs Bellyei
    • 1
    • 2
    Email author
  1. 1.Department of OncologyUniversity of PécsPécsHungary
  2. 2.Department of Biochemistry and Medical ChemistryUniversity of PécsPécsHungary
  3. 3.Veterans Affairs Medical Center and South Florida Veterans Affairs Foundation for Research and EducationMiamiUSA
  4. 4.Department of SurgeryUniversity of PécsPécsHungary
  5. 5.Department of PathologyUniversity of PécsPécsHungary

Personalised recommendations